Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Menu
Sign in
Sign in

FDA-approved Vuity eyedrops could replace your reading glasses

FDA-approved Vuity eyedrops could replace your reading glasses

Just approved by the Food and Drug Administration, Vuity's new product has been found to take effect in as little as 15 minutes.

It’s one of the more irritating side effects of aging: blurred close-up vision, or presbyopia. But a novel therapy, eyedrops that can improve near vision for hours, may help those who’ve gotten tired of wearing reading glasses.

Just approved by the Food and Drug Administration, Vuity's eyedrops have been found to work in as little as 15 minutes, with effects that last up to six hours, according to clinical trial data presented at the annual meeting of the American Society of Cataract and Refractive Surgery this past summer.  

“Vuity is the first and only FDA-approved prescription eyedrop treatment of presbyopia — an age-related blurring of near vision — in adults,” said Dr. George Waring, IV, a LASIK and cataract surgeon and director of the Waring Vision Institute in Mount Pleasant, South Carolina. Waring was a principal investigator for the clinical trials that led to the FDA’s approval of Vuity.

Who are these eyedrops for?

“Nearly half of the U.S. adult population currently lives with presbyopia,” Waring said. “And most people over 40 struggle with some age-related near vision loss.”

The clinical trials showed that the eyedrops were safe and well-tolerated, Waring said, adding that no serious adverse events occurred.

"This is for all patients between 40 and 55 years of age who have presbyopia," said Dr. Ralph Chu, an ophthalmologist based in Minnesota. "So, difficulty seeing near vision. It’s not just reading vision, but it’s our daily activities. It’s eating the food on our plate. It’s putting makeup on in the morning. It’s seeing the dashboard of your car."

How do Vuity eyedrops work?

The eyedrops contain a medication that has been used for more than a hundred years, at a higher concentration, to treat glaucoma, so it’s a drug that doctors have a lot of experience using. The low dose in the Vuity eyedrops works by temporarily decreasing the size of the pupil.

Waring compares this to changing the f-stop on a camera to decrease the size of the opening allowing light to pass to the film in older cameras. “It’s an age-old optical principle that by reducing the aperture extends the range of focus,” he said. “So this increases the ability to read close up while maintaining distance vision.”

Since the smaller pupil allows less light in, the drops are not recommended for use while driving at night, Waring said.

The clinical trials showed that people’s near vision improved. In fact, compared to those who received placebo eyedrops, 22.9% more of those treated with Vuity drops could read at least three more lines on an eye chart than they could before the treatment.   

NBC News correspondent Kristen Dahlgren tried the eyedrops on TODAY. She said the drops burned a little going in and her eyes became red, but within 30 minutes her vision had drastically improved.

December 29, 2021

https://www.today.com/


0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies